Perspective > Medscape Pulmonary Medicine > Viewpoints
A 'Triple' for COPD?
Nicholas Gross, MD, PhD
We cannot cure chronic obstructive pulmonary disease (COPD). However, because advanced COPD causes much disability, acute exacerbations, and mortality and is associated with high cost, we strive to limit those aspects of the condition. To that end, we use all of the pharmaceuticals at our disposal within the limits of avoiding toxic effects.
It has been shown that long-acting beta-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) separately provide symptom relief and reduce acute exacerbations. The addition of an inhaled corticosteroid (ICS) to a LABA provides further relief. These agents bring about benefits in different ways and work at different receptors. It is logical, then, to combine them in our therapies. Thus, fixed combinations of pairs have become standard.
In practice, many patients with severe or very severe COPD already use all three modalities. It is appropriate, therefore, to complete the process and develop a fixed ICS/LABA/LAMA combination—which several pharmaceutical companies are working to construct.
One such company, GlaxoSmithKline, conducted a phase 3 study called FULFIL,[1] which evaluated a fixed combination of fluticasone furoate (the ICS), umeclidinium (the LAMA), and vilanterol (the LABA) in a once-daily formulation. The double-blind study, which enrolled patients with advanced COPD, compared the triple therapy with an approved twice-daily ICS/LABA (budesonide/formoterol) preparation.
In the 24-week trial, the co-primary outcomes were lung function (FEV1) and health status (scores on the St George's Respiratory Questionnaire). The trial found that triple therapy exceeded the lung function and health status by amounts that were statistically and clinically meaningful compared with ICS/LABA.
The study also compared the associated costs of each treatment.[2] Over 52 weeks, unscheduled healthcare requirements were fewer in patients receiving triple therapy than those receiving double therapy. Nondrug costs were lower in patients receiving triple therapy. Both studies were conducted and reported in UK reference costs.
Potential advantages of triple over double therapy include greater lung function and quality of life, with clinically significant differences. Presumably owing to its clinical benefits, triple therapy may also offer cost benefits, although the financial benefit was not very great and results of the FULFIL trial cannot be extended to the health system in the United States.
The ICS/LABA/LAMA fixed combination has the benefit that it combines all the therapeutic advantages of a COPD treatment in a single device which, in this case, needs to be administered only once daily. Together with the convenience of a single daily administration, it will not be possible for patients to skip doses or individual medications. It should be used only in patients with severe or very severe COPD. Correspondingly, there is concern that it will be used inappropriately in patients with less than severe COPD.
Follow Medscape on Facebook and on Twitter @Medscape. Sign up for Medscape Pulmonary Medicine and other newsletters.
Medscape Pulmonary Medicine © 2017 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: A 'Triple' for COPD? - Medscape - Oct 10, 2017.
Professor Emeritus, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois; Volunteer Staff Physician, St Francis Hospital, Hartford, Connecticut
Disclosure: Nicholas Gross, MD, PhD, has disclosed the following relevant financial relationships:
Served as a director, officer, partner, employee, advisor, consultant, or trustee for: DEY; Mylan Laboratories Inc; Boehringer Ingelheim Pharmaceuticals, Inc; GlaxoSmithKline; AstraZeneca Pharmaceuticals LP; Elevation Pharmaceuticals, Inc; ALTANA Pharma US; Almirall Prodesfarma, SA; Forest Laboratories, Inc.
Served as a speaker or a member of a speakers bureau for: DEY; Boehringer Ingelheim Pharmaceuticals, Inc; AstraZeneca Pharmaceuticals LP
Received income in an amount equal to or greater than $250 from: DEY; Mylan Laboratories Inc; Boehringer Ingelheim Pharmaceuticals, Inc; GlaxoSmithKline; AstraZeneca Pharmaceuticals LP; Elevation Pharmaceuticals, Inc; ALTANA Pharma US; Almirall Prodesfarma, SA
Biotech Develops Prescription Software for Mental Health
No Hospital Cost Savings From Bundled MI, HF Medicare Payments
Why Do Doctor-Lawmakers Object to the 9/11 Compensation Fund Bill?
Diseases & Conditions Chronic Obstructive Pulmonary Disease (COPD)
Diseases & Conditions Chronic Obstructive Pulmonary Disease (COPD) and Emphysema in Emergency Medicine
2010spiriva-handihaler-spiriva-respimat-tiotropium-343446
Drugs tiotropium
2001http://www.medscape.com/resource/copd
Chronic Obstructive Pulmonary Disease (COPD) and Emphysema in Emergency Medicine
Fast Five Quiz: How Much Do You Know About COPD?
Fast Five Quiz: Can You Properly Identify and Treat COPD?
An Elderly Man With Dyspnea
E-Cigarettes: A Hard Conversation, but Worth Having
In COPD, Carbon Dioxide Is Often Overlooked
Fewer Hospital Transfers for Nursing Home Residents After National Initiatives
Vaping-Associated Lung Injury Riskier for Older Patients
According to PULMONOLOGISTS
Community-Acquired Pneumonia (CAP) Clinical Practice Guidelines (2019)
Vitamin E Acetate Now Directly Linked to Vaping Injury: CDC
New Pneumonia Guidance: Testing, Treating, and Follow-up
Asthma Clinical Practice Guidelines (GINA, 2019)
Pneumothorax -- Time for New Guidelines?
FDA Approves Trelegy Ellipta for COPD
EMA Panel Backs Two New Inhalers for COPD
CHMP Recommends Triple Combo for COPD Maintenance